Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caleres (CAL) Asset Writedowns and Impairment (2016 - 2025)

Caleres (CAL) has disclosed Asset Writedowns and Impairment for 16 consecutive years, with -$972000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 280.0% to -$972000.0 in Q4 2025 year-over-year; TTM through Nov 2025 was $814000.0, a 73.93% increase, with the full-year FY2025 number at -$815000.0, down 181.5% from a year prior.
  • Asset Writedowns and Impairment was -$972000.0 for Q4 2025 at Caleres, down from $353000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $23.8 million in Q1 2021 to a low of -$1.0 million in Q2 2024.
  • A 5-year average of $2.0 million and a median of $475500.0 in 2024 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 32962.5% in 2021, then plummeted 293.18% in 2024.
  • Caleres' Asset Writedowns and Impairment stood at $1.1 million in 2021, then tumbled by 36.9% to $701000.0 in 2022, then plummeted by 75.04% to $175000.0 in 2023, then skyrocketed by 208.57% to $540000.0 in 2024, then plummeted by 280.0% to -$972000.0 in 2025.
  • Per Business Quant, the three most recent readings for CAL's Asset Writedowns and Impairment are -$972000.0 (Q4 2025), $353000.0 (Q3 2025), and $2.0 million (Q2 2025).